Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors

Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors

Background: Targeted therapy has been established as the standard-of-care for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Among patients with advanced lung cancer, 30–40% have bone metastases (BoM) at first diagnosis. However, lit...

Full description

Bibliographic Details
Main Authors:	Yue-Yun Chen, Pei-Pei Wang, Yang- Fu, Qing- Li, Jiang-Fang Tian, Ting- Liu, Zhen Lin, Zhen-Yu Ding
Format:	Article
Language:	English
Published:	Elsevier 2021-08-01
Series:	Journal of Bone Oncology
Subjects:	Bone metastasis Epidermal growth factor receptor Tyrosine kinase inhibitor Non-small-cell-lung-cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212137421000233

Similar Items

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
by: Wei‐Chun Chen, et al.
Published: (2024-04-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
by: Chia-Yu Kuo, et al.
Published: (2022-12-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
by: Shawyon Ezzati, et al.
Published: (2024-02-01)

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
by: Caiyan Jia, et al.
Published: (2024-01-01)

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
by: Ling Zhang, et al.
Published: (2023-05-01)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
by: Sojung Park, et al.
Published: (2021-01-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
by: Sathishbabu Paranthaman, et al.
Published: (2020-12-01)

Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer
by: JIANG Hanshui, et al.
Published: (2022-12-01)

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
by: Marta Laganà, et al.
Published: (2020-11-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context
by: Rolof G.P. Gijtenbeek, et al.
Published: (2023-04-01)

Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study
by: Hui-Hsia Hsieh, et al.
Published: (2023-02-01)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Katsuhiro Masago, et al.
Published: (2018-01-01)

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
by: Wang Tao, et al.
Published: (2016-01-01)

Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
by: Rahul Shenolikar, et al.
Published: (2023-01-01)

Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
by: Philomena Charlotte Dsouza, et al.
Published: (2017-01-01)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
by: Ying-Yi Chen, et al.
Published: (2023-10-01)

A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management
by: Mohammad Nawaf AlShatnawi, et al.
Published: (2022-12-01)

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
by: Chia-Yu Chu, et al.
Published: (2017-06-01)

Bone Metastases of Gastrointestinal Stromal Tumor: A Review of Published Literature
by: Yang J, et al.
Published: (2020-02-01)

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
by: Chunhua Ma, et al.
Published: (2020-03-01)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
by: Michihito Miyagi, et al.
Published: (2022-12-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
by: Jingwen Wei, et al.
Published: (2022-10-01)

The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases
by: Jianxi Zhou, et al.
Published: (2024-01-01)

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
by: Zhang H
Published: (2016-11-01)

Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer
by: Hongjian Li, et al.
Published: (2017-11-01)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
by: Matthew G. Field, et al.
Published: (2022-06-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
by: Aude I. Ségaliny, et al.
Published: (2015-03-01)

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study
by: John WC Chang, et al.
Published: (2015-06-01)

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy
by: Panpan Lv, et al.
Published: (2020-01-01)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
by: Nobuaki Kobayashi, et al.
Published: (2021-04-01)

Mutation Analysis of Epidermal Growth Factor Receptor Gene in Non-Small Cell Lung Cancer for Selection of Patients Eligible for Tyrosine Kinase Inhibitor Therapy
by: Zeeshan Ansar, et al.
Published: (2023-12-01)

Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors
by: Fu Y, et al.
Published: (2020-11-01)

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
by: Jing-Ren Ye, et al.
Published: (2022-03-01)